Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
about
Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell functionDynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro dataApplication of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemiaBEX1 promotes imatinib-induced apoptosis by binding to and antagonizing BCL-2ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapyTargeting the phosphoinositide 3-kinase pathway in hematologic malignanciesPharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell linesLeptin reverts pro-apoptotic and antiproliferative effects of α-linolenic acids in BCR-ABL positive leukemic cells: involvement of PI3K pathwayRegulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemiaPerifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro.Targeted inhibition of kinases in cancer therapyExpression patterns of microRNAs associated with CML phases and their disease related targets.Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABLOncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia.The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease.Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cellsmTOR signaling: implications for cancer and anticancer therapy.Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathwayPotentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors.Investigating mammalian target of rapamycin inhibitors for their anticancer properties.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsTherapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Small molecule signal transduction inhibitors for the treatment of solid tumors.A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemiaMammalian target of rapamycin (mTOR) pathway signalling in lymphomas.Targeting survival pathways in chronic myeloid leukaemia stem cellsCombination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.Current status of agents active against the T315I chronic myeloid leukemia phenotype.Mammalian target of rapamycin as a target in hematological malignancies.Role of epigenetics in chronic myeloid leukemiaChanges in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.
P2860
Q28246944-967B5CE5-6646-4B66-B34B-18EBB741032FQ28478542-2EA6FAA1-B8D5-4227-B6B0-CE8F55FAE9D6Q28534259-E0CAB951-3224-4693-9372-AAEE0D2F1CBAQ31153995-3DDFC15B-9004-4CF5-92F5-6FE811171C5CQ33476874-84CD99B8-D1EB-436C-BAB9-BE6F2A2F2A03Q33558141-752D21E3-AB1A-4F17-A372-9CFCA2C7B86CQ33597393-8A63EB7E-7D61-4591-AEE5-827F0921F37DQ33618630-2D94C158-4207-4A3C-835D-94D7F2F40A9CQ34047043-125E7AA1-3DD4-4BD3-8AAD-90D2C11BE78AQ34076003-170E402C-52A4-4CDB-B61A-4A4C9C87A96DQ34190803-228C1F9A-E644-4E65-973A-317DC6DC2432Q34683348-0D97A376-D790-44B2-92A3-41DEFEAF10AEQ35009176-9FF66B9C-4D5A-4BCD-B78D-677E2287D128Q35596540-6660F69D-9196-4027-860B-BCD02661ADF9Q35635226-24D46291-397B-4CF8-865F-3555D9700885Q35683215-CE5E0E3D-04E6-48B9-8808-1B15D0A4BCEAQ35773205-43D828B6-9ACB-4304-AB32-5CFE2F641C21Q36228076-B90D7282-026C-4717-B679-D6756A396C46Q36240238-4F62D002-7369-4DB0-97B0-2BF9ED4DF9B0Q36365093-5480ABEF-557D-402F-B57C-791F7A9AC992Q36384328-0870D8BE-DAA5-41C4-A27F-FEA854F16954Q36508937-28924F9B-8AEA-40D0-B448-04D21766EE7BQ36597361-8DEB29E0-3C3B-4E27-8E01-5EDD68A6A50DQ36600294-575C7C13-2DFF-4491-8E4D-D9152314DD57Q36740744-BA17A5DD-D2C6-4520-A1B6-2E188FD426A9Q36822880-9B3D2BEE-0748-4F42-8F4A-5DADF23EB65BQ36895413-FD4612EB-9A20-4D03-AA8C-5399C74C63BBQ37073009-1E9CA637-D524-47BE-8983-BF7F8ABB1D5FQ37074284-41A4FD04-11A0-421E-A122-4B2C828AEEB7Q37122686-55BE1C40-3D46-42D0-8AF2-98836F208B18Q37619710-C66ED245-CEC0-45A3-8063-E2A2F8D596FDQ37663655-D68EE728-F3A9-452E-9AE7-FE651E1B53EFQ37836931-607DA4A6-CFFC-443F-9D38-A498221E681FQ37847179-5775BC01-3FEA-4AF0-8233-004AC2EE6432Q37866136-E7F12BA4-1B59-45C7-957B-06B7CA8817F2Q38072315-6F601C45-BA53-4005-90CB-3DA4B4160A97Q38133575-36EAC4AF-E1F4-4AD3-ABB9-C5519FB7581AQ38218128-E81E91A7-E0A7-451E-A860-280D970D712BQ38233425-38CA30DB-8A43-4E7E-B5C5-2644A7324DEFQ38363058-EEDE2E1A-07CB-44E3-9E0E-80A0C5274437
P2860
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
@en
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
@nl
type
label
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
@en
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
@nl
prefLabel
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
@en
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
@nl
P2093
P2860
P356
P1433
P1476
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
@en
P2093
Burchert A
Müller-Brüsselbach S
Neubauer A
von Bubnoff N
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403898
P577
2005-10-01T00:00:00Z